CAR T-Cell Therapy

>

Latest News

Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma
Cilta-cel is Safe, Feasible in Outpatient Settings for R/R Multiple Myeloma

July 16th 2024

Taiga Nishihori, MD, discussed the current outpatient administration model of cilta-cel among patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy Remains Underutilized, Despite Improvements in Access
CAR T-Cell Therapy Remains Underutilized, Despite Improvements in Access

July 10th 2024

New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival
New Hope for Multiple Myeloma: Cilta-Cel Improves Overall Survival

July 2nd 2024

Following FDA’s Call for CAR T Boxed Warnings, Questions About Secondary Cancers Linger
Following FDA’s Call for CAR T Boxed Warnings, Questions About Secondary Cancers Linger

June 25th 2024

Optimizing Cellular Therapy Programs for Community Practices
Optimizing Cellular Therapy Programs for Community Practices

April 22nd 2024

Video Series
Video Interviews

More News